Shares of nano-cap biotech Aikido Pharma Inc AIKI, are ripping higher following an announcement concerning worldwide licensing of an antiviral platform.
Aikido said it has exercised the option to license from the University of Maryland Baltimore, the broad-spectrum antiviral platform, which is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens.
The technology will inhibit replication of multiple viruses, including influenza virus, SARS-COV, MERS-COV, ebola virus and Marburg virus, it added.
The execution of the initial option agreement was announced by Aikido, which was then known as Spherix Pharma, in early March.
"We continue to vet the technology we optioned, but this antiviral drug platform technology we've licensed is broader with more potential applicability, while also coming from the same lead inventors and institution," said Anthony Hayes, CEO of Aikido.
"We will continue to investigate the technology covered by our option and we will be providing additional information about this antiviral platform shortly."
Aikido shares were skyrocketing 200% to $2.01 Tuesday morning but pulled back to trade up about 38% to 93 cents at time of publication.
Related Links:
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
